Browse

Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis

DC Field Value Language
dc.contributor.authorHong, Junshik-
dc.contributor.authorHan, Sae-Won-
dc.contributor.authorHam, Hye Seon-
dc.contributor.authorKim, Tae-Yong-
dc.contributor.authorChoi, In Sil-
dc.contributor.authorKim, Byung-Su-
dc.contributor.authorOh, Do-Youn-
dc.contributor.authorIm, Seock-Ah-
dc.contributor.authorKang, Gyeong Hoon-
dc.contributor.authorBang, Yung-Jue-
dc.contributor.authorKim, Tae-You-
dc.date.accessioned2021-01-31T11:05:42Z-
dc.date.available2021-01-31T11:05:42Z-
dc.date.created2020-12-21-
dc.date.created2020-12-21-
dc.date.issued2011-06-
dc.identifier.citationCancer Chemotherapy and Pharmacology, Vol.67 No.6, pp.1323-1331-
dc.identifier.issn0344-5704-
dc.identifier.other119289-
dc.identifier.urihttps://hdl.handle.net/10371/173019-
dc.description.abstractTo evaluate the efficacy and safety of S-1 in combination with oxaliplatin in a biweekly schedule as first-line treatment in metastatic colorectal cancer and the association between genetic polymorphisms and treatment outcomes. Eligibility included age 18-75 years, at least one measurable lesion, no prior chemotherapy except adjuvant chemotherapy, and Eastern Cooperative Oncology Group Performance Status (PS) 0-2. S-1 40 mg/m(2) b.i.d. on days 1-7 with 85 mg/m(2) of oxaliplatin on day 1 was repeated every 2 weeks. Genomic DNA from whole blood was analyzed for 15 single-nucleotide polymorphisms (SNPs) among 8 genes. Fifty-two patients (median age 63 years, range 37-74) were enrolled: 37 men and 15 women; 44 with a PS of 0 and 8 with a PS of 1; and 41 with initially metastatic cancer and 11 with relapsed disease. Among 51 evaluable patients, objective response rate was 47.1% [95% confidence interval (CI) 32.9-61.2]. Median follow-up duration was 17.1 months (range 3.9-28.2 months). Median progression-free survival (PFS) was 6.4 months (95% CI 4.8-8.1), and median overall survival had not been reached yet. Reported grade 3 toxicities were neutropenia (7.7%), thrombocytopenia (5.8%), sensory neuropathy (7.7%) and diarrhea (1.9%). There was no grade 4 toxicity or neutropenic fever. Patients with A/G or G/G genotype in GSTP1 Ile105Val SNP had longer PFS than patients with A/A (median 8.3 vs. 6.1 months, P = 0.04). Biweekly S-1 with oxaliplatin is effective and has improved tolerability and convenience compared to other fluoropyrimidine with oxaliplatin combinations. GSTP1 Ile105Val SNP is associated with treatment outcomes.-
dc.language영어-
dc.publisherSpringer Verlag-
dc.titlePhase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis-
dc.typeArticle-
dc.contributor.AlternativeAuthor임석아-
dc.identifier.doi10.1007/s00280-010-1425-7-
dc.citation.journaltitleCancer Chemotherapy and Pharmacology-
dc.identifier.wosid000291036500012-
dc.identifier.scopusid2-s2.0-79959592515-
dc.citation.endpage1331-
dc.citation.number6-
dc.citation.startpage1323-
dc.citation.volume67-
dc.identifier.sci000291036500012-
dc.description.isOpenAccessN-
dc.contributor.affiliatedAuthorOh, Do-Youn-
dc.contributor.affiliatedAuthorIm, Seock-Ah-
dc.contributor.affiliatedAuthorKang, Gyeong Hoon-
dc.contributor.affiliatedAuthorBang, Yung-Jue-
dc.contributor.affiliatedAuthorKim, Tae-You-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.subject.keywordPlusGLUTATHIONE-S-TRANSFERASE-
dc.subject.keywordPlusTHYMIDYLATE-SYNTHASE-
dc.subject.keywordPlus1ST-LINE THERAPY-
dc.subject.keywordPlusCUMULATIVE NEUROPATHY-
dc.subject.keywordPlusPLUS OXALIPLATIN-
dc.subject.keywordPlusORAL S-1-
dc.subject.keywordPlusPOLYMORPHISM-
dc.subject.keywordPlusSURVIVAL-
dc.subject.keywordPlusFLUOROURACIL-
dc.subject.keywordPlusASSOCIATION-
dc.subject.keywordAuthorColorectal cancer-
dc.subject.keywordAuthorOxaliplatin-
dc.subject.keywordAuthorS-1-
dc.subject.keywordAuthorChemotherapy-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Dept. of Medicine (의학과)Journal Papers (저널논문_의학과)
Graduate School of Convergence Science and Technology (융합과학기술대학원)Dept. of Molecular and Biopharmaceutical Sciences (분자의학 및 바이오제약학과)Journal Papers (저널논문_분자의학 및 바이오제약학과)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse